补肾生血方减轻化疗血液学毒性反应临床研究
|
摘要
随着肿瘤化疗方案应用进展,化疗已成为肿瘤临床综合治疗重要手段之一。但化疗药物所造成血细胞减少严重影响化疗正常进行,从而导致临床疗效降低。化疗后血象明显减少的出现,不但降低肿瘤患者生活质量,而且严重影响抗肿瘤疗效和预后。本论文以中医理论为基础,探讨了化疗血细胞减少病因病机,治则治法;综述了近10年来西医关于造血调控与骨髓抑制的研究进展,以及中药促进骨髓造血研究进展;采用前瞻性、随机、自身对照研究方法,客观地评估了补肾生血方防治化疗药物导致血象减少临床疗效。
采用自身对照研究方法,收集36例患者,72个化疗病例。分为试验组(A组)和对照组(B组)。A组选用中药(补肾生血方)加化疗,B组单纯化疗。按随机数字方法,确定每个入选病例治疗方案,即为先A组,后B组;或先B组,后A组。试验组(A组)于化疗周期前1周开始口服补肾生血方,2次/日,连续用药3周,至化疗后1周停药。两组若白细胞低于3.0×109/L,开始予以G-CSF75ug,皮下注射,连续注射3～7天后停药。
研究结果表明:①中医症状总评分,试验组痊愈10例,占27.78%;显效16例,占44.44%;有效8例,占22.22%;无效者2例,占5.56%;总显效率和总有效率分别为72.22%和94.44%。对照组痊愈3例,占8.33%;显效7例,占19.44%;有效8例,占22.22%;无效18例,占50%;总显效率和总有效率分别为27.78%和50%。经Wilcoxon非参数检验,试验组中医症状有效率明显优于对照组(P<0.001)。②中医主要单项症状神疲乏力、腰膝酸软、食欲减退、食后腹胀、五心烦热、面色无华,试验组治疗后比治疗前明显改善(P<0.05),但头晕耳鸣、夜尿频多症状比治疗前有所好转,无统计学意义(P>0.05);对照组治疗前后比较,无统计学意义(P>0.05)。③血象变化,化疗后两组WBC和GRAN均值比较,试验组WBC和GRAN在化疗后第7天、第10天、第15天的数值明显高于对照组(P<0.05)。两组WBC和GRAN在化疗后第7天、第10天数值分别与化疗前数值差值比较,试验组WBC和GRAN数值在第7天、第10天的下降均明显低于对照组(P<0.05);两组Hb、PLT治疗前后比较,均无统计学意义(P>0.05);④KPS评分变化比较,两组化疗后中位KPS评分分别为80分(试验组)和60分(对照组)。试验组KPS评分改善25例(69.44%),稳定6例(16.67%),下降5例(13.89%),有效率达69.44%;对照组改善10例(27.78%),稳定10例(27.78%),下降16例(44.44%),有效率为27.78%,经秩和检验,试验组人体功能状态改善情况明显优于对照组(P<0.001)。⑤化疗血液学毒性反应分度比较,试验组未发生血液学毒性反应者11例(30.56%),发生血液学毒性反应者共25例(69.44%),其中Ⅰ度者22例,占88%;Ⅱ度者3例,占12%,无1例发生Ⅲ/Ⅳ度血液学毒性反应;血液学毒性反应发生率69.44%。对照组未发生血液学毒性反应者4例(11.11%),发生血液学毒性反应者共32例(88.89%),其中Ⅰ度者20例,占62.5%;Ⅱ度者8例,占25%;Ⅲ度者4例,占11.11%;Ⅳ度者0例;血液学毒性反应发生率88.89%,经秩和检验,试验组血液学毒性反应分度明显低于对照组(P<0.05)。⑥化疗后副反应,恶心呕吐及肝肾功能损害等情况两组之间比较,均无统计学意义(P>0.05)。⑦因子分析显示,两组均以神疲乏力、食欲减退、食后腹胀、头晕耳鸣、面色无华等为主要临床表现,结合舌脉分布情况提示,脾肾亏虚,瘀血阻滞是化疗后血细胞减少病机关键。⑧化疗血液学毒性反应发生的相关因素分析,多元线性回归分析表明,化疗血液学毒性反应发生与TNM分期和曾否接受过放化疗呈线性正相关,其中TNM分期对化疗血液学毒性反应发生影响较大。
结论:①补肾生血方能预防化疗白细胞减少发生,减轻化疗白细胞降低程度;②补肾生血方能缓解中医临床症状,改善患者体能状态,提高生存质量。③补肾生血方具有较好临床安全性,应进一步深入研究。
The author here presented her theoretical and primary clinical studies on the treatment of chemotherapy-followed hematology toxicity reaction with Bushen Shengxue Fang.
In the part of theoretical study,the paper presented and analyzed the opinions of TCM about the etiology, pathogenesis,therapeutic principles and prescriptions of chemotherapy-followed blood cell decrease.It also summarized the general situation of the research on the chemotherapy-followed bone marrow depression especially in the near 10 years.
Chemotherapy-followed blood cell decrease belongs to Weakness and Blood Deficiency in TCM.We think that its pathological mechanism mainly resulting from deficiency of spleen and kidney and stagnation of blood stasis,therefore the therapy principle is tonifying the kidney and invigorating the spleen,nourishing the blood and promoting blood circulation.
In the part of clinical study,36 patients with the cancer needed chemotherapy were divided into test group and control group randomly.Test group was treated with Bushen Shengxue Fang (Decoction of Tonifying the Kidney and Hemogenesis),one week before, during and one week after chemotherapy.Control group was treated with Granulocyte colony stimulating factor (G-CSF),3-7 days, once leucocytes dropped bellow 3000×109/L after chemotherapy. The result shows:①The total scores of TCM symptoms grades.The test group of which 10 cases recovered,accounting for 27.78%,and excellence cases were 16,accounting for 44.44%,the effective cases was 8 case,accounting for 22.22%,while the numbers of ineffectiveness were 2 cases, accounting for 5.56%, in which the total rates of effective were 94.44%.Three cases of the control group were recovered,accounting for 8.33%,7 cases were excellence,accounting for 19.44%,8 cases were effective,accounting for 22.22%,while 18 cases were ineffectiveness, accounting for 50%,in which the total rates of effective were 50%,respectively.The effective rate of test group on TCM symptom was significantly higher than that of on control group (P<0.001).②The main TCM individual symptoms were weak, anorexia,abdominal distention after eating, hot sensation in the five hearts,dim complexion. All of these symptoms of the test group were obviously improved(P<0.05),but the difference of dizziness and tinnitus and nocturia more between before and after treatment had no statistically significant (P>0.05),At the same time,the control group made no significant difference after treatment(P>0.05),While there was a significant difference(P<0.05)between the test group and the control group,after treatment.③After chemotherapy,The means of WBC and GRAN in test group were obviously higher than control group on the 7th,10th and 15thafter chemotherapy (P<0.05).The changes of Hb and PLT in these two groups had no obviously difference before and after the chemotherapy (P>0.05).④Score of Karnofsky performance status(KPS).The median of KPS scores of these two groups after chemotherapy were 80 scores (the test group) and 60 scores (the control group), respectively.25 cases of KPS scores in Test Group were improved (69.44%),6 cases were stable(16.67%),5 cases were decreased(13.89%),and the effective rate was 69.44%.While 10 cases of control group were improved (27.78%),10 cases were stable (27.78%),16 cases were decreased (44.44%),and the effective rate was 27.78%.It was validated by Wilcoxon nonparametric test that the treated group gain superior in KPS(P<0.001).⑤The degree of chemotherapy-followed hematology toxicity reaction.the cases of the patients in test group developed hematology toxicity reaction was 25(69.44%),of which the number ofⅠdegree was 22 cases,while the number ofⅡdegree was 3 cases,and none of the patients developed III / IV degree,the incidence rate of hematology toxicity reaction was 69.44%.While 32 cases of control group developed to hematology toxicity reaction (88.89%).of which the number ofⅠdegree was 24 cases, the number ofⅡdegree was 8 cases, the number ofⅢdegree was 4 cases, the number ofⅣdegree was none,the totle incidence rate of hematology toxicity reaction was 88.89%.The degree of hematology toxicity reaction occurrence in test group was significantly lower than that of in control group (P<0.05).⑥As for side-effects after the chemotherapy.The cases of leukopenia and neutropenia between these two groups were significant difference (P>0.05) while hemoglobin Decrease,thrombocytopenia, nausea and vomiting,liver and kidney function lesion between these two groups had no significant difference (P>0.05).⑦Factor analysis make it clear that the main clinical manifestations are lack of vitality,lassitude,loss of appetite,abdominal distention,dizziness,tinnitus,dim complexion and so on,which clue to the pivotal pathogenesis of chemotherapy-followed blood cell decrease on insufficiency of spleen and kidney and stagnation of blood stasis just as inspection of tongue and pulse taking do.⑧Analysed by multiple linear regression,we can inspect that chemotherapy-followed hematology toxicity reaction is positive linear correlation with TNM grade and whether or not has received the treatment of chemotherapy and radiotherapy,furthermore,TNM grade engender maximal influence to chemotherapy-followed hematology toxicity reaction.
Conclusion:①Bushen Shengxue Fang effective in preventing and alleviating chemotherapy-followed neutropenia and leukopenia.②Bushen Shengxue Fang could effectually alleviate TCM clinical symptoms, improve physical condition of patients,and improve quality of life for patients suffering from cancer chemotherapy-followed blood cell decrease③Bushen Shengxue Fang has a better clinical safety.
采用自身对照研究方法,收集36例患者,72个化疗病例。分为试验组(A组)和对照组(B组)。A组选用中药(补肾生血方)加化疗,B组单纯化疗。按随机数字方法,确定每个入选病例治疗方案,即为先A组,后B组;或先B组,后A组。试验组(A组)于化疗周期前1周开始口服补肾生血方,2次/日,连续用药3周,至化疗后1周停药。两组若白细胞低于3.0×109/L,开始予以G-CSF75ug,皮下注射,连续注射3～7天后停药。
研究结果表明:①中医症状总评分,试验组痊愈10例,占27.78%;显效16例,占44.44%;有效8例,占22.22%;无效者2例,占5.56%;总显效率和总有效率分别为72.22%和94.44%。对照组痊愈3例,占8.33%;显效7例,占19.44%;有效8例,占22.22%;无效18例,占50%;总显效率和总有效率分别为27.78%和50%。经Wilcoxon非参数检验,试验组中医症状有效率明显优于对照组(P<0.001)。②中医主要单项症状神疲乏力、腰膝酸软、食欲减退、食后腹胀、五心烦热、面色无华,试验组治疗后比治疗前明显改善(P<0.05),但头晕耳鸣、夜尿频多症状比治疗前有所好转,无统计学意义(P>0.05);对照组治疗前后比较,无统计学意义(P>0.05)。③血象变化,化疗后两组WBC和GRAN均值比较,试验组WBC和GRAN在化疗后第7天、第10天、第15天的数值明显高于对照组(P<0.05)。两组WBC和GRAN在化疗后第7天、第10天数值分别与化疗前数值差值比较,试验组WBC和GRAN数值在第7天、第10天的下降均明显低于对照组(P<0.05);两组Hb、PLT治疗前后比较,均无统计学意义(P>0.05);④KPS评分变化比较,两组化疗后中位KPS评分分别为80分(试验组)和60分(对照组)。试验组KPS评分改善25例(69.44%),稳定6例(16.67%),下降5例(13.89%),有效率达69.44%;对照组改善10例(27.78%),稳定10例(27.78%),下降16例(44.44%),有效率为27.78%,经秩和检验,试验组人体功能状态改善情况明显优于对照组(P<0.001)。⑤化疗血液学毒性反应分度比较,试验组未发生血液学毒性反应者11例(30.56%),发生血液学毒性反应者共25例(69.44%),其中Ⅰ度者22例,占88%;Ⅱ度者3例,占12%,无1例发生Ⅲ/Ⅳ度血液学毒性反应;血液学毒性反应发生率69.44%。对照组未发生血液学毒性反应者4例(11.11%),发生血液学毒性反应者共32例(88.89%),其中Ⅰ度者20例,占62.5%;Ⅱ度者8例,占25%;Ⅲ度者4例,占11.11%;Ⅳ度者0例;血液学毒性反应发生率88.89%,经秩和检验,试验组血液学毒性反应分度明显低于对照组(P<0.05)。⑥化疗后副反应,恶心呕吐及肝肾功能损害等情况两组之间比较,均无统计学意义(P>0.05)。⑦因子分析显示,两组均以神疲乏力、食欲减退、食后腹胀、头晕耳鸣、面色无华等为主要临床表现,结合舌脉分布情况提示,脾肾亏虚,瘀血阻滞是化疗后血细胞减少病机关键。⑧化疗血液学毒性反应发生的相关因素分析,多元线性回归分析表明,化疗血液学毒性反应发生与TNM分期和曾否接受过放化疗呈线性正相关,其中TNM分期对化疗血液学毒性反应发生影响较大。
结论:①补肾生血方能预防化疗白细胞减少发生,减轻化疗白细胞降低程度;②补肾生血方能缓解中医临床症状,改善患者体能状态,提高生存质量。③补肾生血方具有较好临床安全性,应进一步深入研究。
The author here presented her theoretical and primary clinical studies on the treatment of chemotherapy-followed hematology toxicity reaction with Bushen Shengxue Fang.
In the part of theoretical study,the paper presented and analyzed the opinions of TCM about the etiology, pathogenesis,therapeutic principles and prescriptions of chemotherapy-followed blood cell decrease.It also summarized the general situation of the research on the chemotherapy-followed bone marrow depression especially in the near 10 years.
Chemotherapy-followed blood cell decrease belongs to Weakness and Blood Deficiency in TCM.We think that its pathological mechanism mainly resulting from deficiency of spleen and kidney and stagnation of blood stasis,therefore the therapy principle is tonifying the kidney and invigorating the spleen,nourishing the blood and promoting blood circulation.
In the part of clinical study,36 patients with the cancer needed chemotherapy were divided into test group and control group randomly.Test group was treated with Bushen Shengxue Fang (Decoction of Tonifying the Kidney and Hemogenesis),one week before, during and one week after chemotherapy.Control group was treated with Granulocyte colony stimulating factor (G-CSF),3-7 days, once leucocytes dropped bellow 3000×109/L after chemotherapy. The result shows:①The total scores of TCM symptoms grades.The test group of which 10 cases recovered,accounting for 27.78%,and excellence cases were 16,accounting for 44.44%,the effective cases was 8 case,accounting for 22.22%,while the numbers of ineffectiveness were 2 cases, accounting for 5.56%, in which the total rates of effective were 94.44%.Three cases of the control group were recovered,accounting for 8.33%,7 cases were excellence,accounting for 19.44%,8 cases were effective,accounting for 22.22%,while 18 cases were ineffectiveness, accounting for 50%,in which the total rates of effective were 50%,respectively.The effective rate of test group on TCM symptom was significantly higher than that of on control group (P<0.001).②The main TCM individual symptoms were weak, anorexia,abdominal distention after eating, hot sensation in the five hearts,dim complexion. All of these symptoms of the test group were obviously improved(P<0.05),but the difference of dizziness and tinnitus and nocturia more between before and after treatment had no statistically significant (P>0.05),At the same time,the control group made no significant difference after treatment(P>0.05),While there was a significant difference(P<0.05)between the test group and the control group,after treatment.③After chemotherapy,The means of WBC and GRAN in test group were obviously higher than control group on the 7th,10th and 15thafter chemotherapy (P<0.05).The changes of Hb and PLT in these two groups had no obviously difference before and after the chemotherapy (P>0.05).④Score of Karnofsky performance status(KPS).The median of KPS scores of these two groups after chemotherapy were 80 scores (the test group) and 60 scores (the control group), respectively.25 cases of KPS scores in Test Group were improved (69.44%),6 cases were stable(16.67%),5 cases were decreased(13.89%),and the effective rate was 69.44%.While 10 cases of control group were improved (27.78%),10 cases were stable (27.78%),16 cases were decreased (44.44%),and the effective rate was 27.78%.It was validated by Wilcoxon nonparametric test that the treated group gain superior in KPS(P<0.001).⑤The degree of chemotherapy-followed hematology toxicity reaction.the cases of the patients in test group developed hematology toxicity reaction was 25(69.44%),of which the number ofⅠdegree was 22 cases,while the number ofⅡdegree was 3 cases,and none of the patients developed III / IV degree,the incidence rate of hematology toxicity reaction was 69.44%.While 32 cases of control group developed to hematology toxicity reaction (88.89%).of which the number ofⅠdegree was 24 cases, the number ofⅡdegree was 8 cases, the number ofⅢdegree was 4 cases, the number ofⅣdegree was none,the totle incidence rate of hematology toxicity reaction was 88.89%.The degree of hematology toxicity reaction occurrence in test group was significantly lower than that of in control group (P<0.05).⑥As for side-effects after the chemotherapy.The cases of leukopenia and neutropenia between these two groups were significant difference (P>0.05) while hemoglobin Decrease,thrombocytopenia, nausea and vomiting,liver and kidney function lesion between these two groups had no significant difference (P>0.05).⑦Factor analysis make it clear that the main clinical manifestations are lack of vitality,lassitude,loss of appetite,abdominal distention,dizziness,tinnitus,dim complexion and so on,which clue to the pivotal pathogenesis of chemotherapy-followed blood cell decrease on insufficiency of spleen and kidney and stagnation of blood stasis just as inspection of tongue and pulse taking do.⑧Analysed by multiple linear regression,we can inspect that chemotherapy-followed hematology toxicity reaction is positive linear correlation with TNM grade and whether or not has received the treatment of chemotherapy and radiotherapy,furthermore,TNM grade engender maximal influence to chemotherapy-followed hematology toxicity reaction.
Conclusion:①Bushen Shengxue Fang effective in preventing and alleviating chemotherapy-followed neutropenia and leukopenia.②Bushen Shengxue Fang could effectually alleviate TCM clinical symptoms, improve physical condition of patients,and improve quality of life for patients suffering from cancer chemotherapy-followed blood cell decrease③Bushen Shengxue Fang has a better clinical safety.
引文
1 The International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer.Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer . J Infect Dis, 1978, 137; 14-29.
2 Pizzo PA, Hathorn Jw, Hiemenz, et al.A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med, 1987, 315; 552-8.
3 Talcott JA, Siegel RD , Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutopenia: A prospective two-center validation of a prediction rule. J Clin Oncol.1992 .10:316-22, 1992
4 RechtA, Come SE, Gelman RS, Goldstein.m, Tishler S, Gotes Sm, Abner AL, Vicini FA, SilverB, Connolly JL, Schnitt SJ, Coloman NC, Harris JR. Integration of conservation of conservative surgery, radiotherapy and chemotherapy for the treament of early stage, node positive breast cancer, sequencing timing and outcome. [J]Clin Oncol, 1991.9; 1662.
5 Fyles A, Keane TJ, Barton M, Simmj.The effect of treament duration in the local control of cervix cancer. Radiother Oncol .1992.25; 273 1992
6 Cox JD, Dajak TF, Asbells, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M 3rd: Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unrecases from 3 Radiation therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys.1993.27; 493.
7 Wang CC, Efird JT. Dose prolonged treament course adversely affect local control of carcinoma of the larynx.Int J Radiat Oncol Biol Phys,1994,29;657.
8 Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy Int J Radiat Oncol Biol Phys, 1992, 23; 457.
9 Ma Cormick B. Radition therapy for breast cancer. Curr Opin Oncol, 1993,.5; 976.
10 Turrisi AT 3rd. Platnum combined with radiation therapy in small cell lung cancer: Focusing like a laser beam on crucial issues. Semin Onco, 1994, 21; 34
11 Cullen MH.Trials of radiotherapy versus chemotherapy plus redical radiotherapy in non-small cell lung cancer. Semin Oncol, 1994, 21; 34,
12 Taylor SG. Chemotherapy in the multimodality treament of head and neck cancer, in Kagan AR, Miles J (eds): Head and neck Oncology: Clinical Management.Elmsford, NY, Pergamon, 1989, p166.
13 Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophsgus. N Engl J Med1992,326;1593,
14 Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Adjuvant therapy of resected andenocarcinoma of the pancreas.Int J Radiat Oncol Biol Phy1991,21;1137.
15 O’Connell MJ, Mayer RJ, Gunderson JA, Wieand HS,Krook JE, Macdonald JS, Haller DG, Mayer RJ, underson LL, Rich TA.Improving adjuvant therapy for rectal cancer by combiling protracted-infusion fluorouracil with radiation therapy after curative surgey.N’sEngl J Med1994, 331:502, 1994.
16 RechtA, Come SE, Gelman RS, Goldstein.m, Tishler S, Gotes Sm, Abner AL, Vicini FA, SilverB, Connolly JL, Schnitt SJ, Coloman NC, Harris JR. Integration of conservation of conservative surgery, radiotherapy and chemotherapy for the treament of early stage, node positive breast cancer, sequencing timing and outcome. J Clin Oncol 1991, 9; 1662.
17 Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Homing SJ.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin disease: A preliminary report. J Clin Oncol, 1995, 13; 1080.
18 Grawford J,Ozer H,Stoller R,et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med, 1991, 325; 164.
19 候俊卿,段玉龙,史中州.胚胎胸腺移植在恶性肿瘤治疗中的应用.中国肿瘤临床康复1996,2(4);41-42.
20 Knutson S In vitro grouth of granulocyte colonies from circulating cells in cord biood, 1947, 43; 357.
21刘欣,孙自敏.静脉丙种球蛋白(IVIG)预防恶性血液病化疗后感染的临床评价(附46例报告).哈尔滨药,2000,20(1);1.
22 Dicke KA, Spitzer G, Evaluation of the use of high dose cytoreduction with auto logo us marrow rescue in various malignancies [J].Transplantation,1986,41(1);4—20.
23 哈森,肖镇.自体骨髓移植在实体瘤治疗中的应用研究.A cta Acad Med N eiM ongol Dec.2002, 24(4);248.
24 Hanun YA. Apoptosis and the dilemma of cancer chemotherapy [J] Blood, 1997, 89(6); 1845-1853.
25 Hanun YA. Apoptosis and the dilemma of cancer chemotherapy [J] .Blood, 1997, 89(6); 1845-1853.
26 Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis [J]. Annu Rev Physion, 1998, 60; 619-642.
27 王振义,陈竺主编.肿瘤的诱导分化和凋亡疗法.上海科学技术出版社出版第 1 版.1998, 158-160.
28 田卫卫.化瘀补虚方改善化疗后小鼠骨髓抑制机制研究.成都中医药大学博士学位论文,2003.
29 Crawford J, Ozer H, stoller R, et al. Reduction by granulocy t colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med, 1991, 325;164.
30 哈敏文,何安光.黄芪合剂防治化疗性骨髓抑制的实验研究.中国医科大学学报, 1997, 26(5);449-452.
31 Jerome EG,Loretta MI.Chemotherapy-Induced Anemia in Adults.Incidence and Treatment.J Natl Cancer Inst,1999,91;1616～1634.
32 Gale RP. Auto logo us bone marrow transplantation in patients with cancer [J]. JAMA,1980; 243(6):540-542.
33 孙燕主编.内科肿瘤学.人民卫生出版社,265-266.
34 Blay JY, Chauvin Fet al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Dncol, 1996, 14:636-643.
35 Michael Mac et al. Radiotherapy—associated neutopenia and thrombocy topenia: Analysis of risk factors and development of a predictive model. Blood, 1997, 89; 2303-2310.
36 郭艳霞,于成宝,刘秋菊.化疗后骨髓抑制预测性模型的建立.吉林医学, 2005, 26(12); 1257-1259.
37 Michael Mac et al. Radiotherapy—associated neutopenia and thrombocy topenia: Analysis of risk factors and development of a predictive model. Blood, 1997, 89; 2303-2310.
38 Watkins SM. Predicting neutropenia after chemotherapy for lymphoma. Leuk Lymphoma, 1994, 9; 107-109.
39 Kitay—Cohen Y,Lishner M,she lef A,et al.Bone marrow involvement, in intensively treated patient with intermediate grade non-Hodgkin’s lymphoma, is a risk factor for granulocy topenia and fever. Leuk Lymphoma. 1996, 20; 333-336.
40 Silber JH, Fridman M, Dipaola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol, 1998, 16; 2392-2400.
41 Eric Voog et al. Factors that predict chemotherapy-induced myelosuppression in lymphoma Patients: Role of the tumor necrosis factor ligand-receptor system. J Clin Oncol, 2003, 18; 325-331.
42 刘秋菊,姜玉珍,贾娇源.化放疗后骨髓抑制危险因素分析.江西医学院学报, 2005,45 (3); 48-50.
43 韩瑞刚,彭瑞云.电离辐射对骨髓损伤的研究进展.中华放射医学与防护杂志, 2005, 25 (6);586～588.
44 Cella D, Dobrez D,Giaspy J.Control of cancer related anemia with erythropoietin agents:a review of evidence for improved quality of life and clinical outcomes.Ann Oncol, 2003, 14 (4);511～519.
45 Cohen HJ.Geriatric principles of treatment applied to medical oncology.an overview.Semin Oncol,1995,22(suppl 1);1～2.
46 Vose JM.Cytokineuse in the older patient.Semin Oncol,1995,22(suppl 1);6～8.
47 Cella D.Factors influencing quality of life in cancer patients Anemia and fatigue.Semin Oncol,1988,2s;43～46.
48 Loretta MItri.Ortimal Hemoglobin level for cancer patients.semin oncol,2000,27 (supple 4); 12～15.
49 Winninghan ML,Nail LM,Burke MB,et al.Fatigue and the cancer experience the state of the knowledge.Oncol Nurs Forum,1994,21;23～36.
50 Krishnasamy M.Social support and the patient with cancer:a consideration of theliterature .Adv Nurs,1999,23(4);757～762.
51 Cawford J, Ozer H, Stoller R, et al. Reduction by granulocyt colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med, 1991, 325; 164.
52 Longo DL, Devita VT, Jaffe ES, et al. Toxicities of therapy for aggressive lymphomas. Devita VT Jr, Cancer Principles&Practice of Oncology. 4th Edtition JB Lippincott, Philadelphia, 1993.
53 王笑天.癌证患者的瘀血证与血液高凝状态的研究.中国中西医结合学会活 血化瘀研究学会编.血液证与活血化瘀研究.北京.学苑出版社,1990;260.
54 李佩文,赵建成.恶性肿瘤并发症实用疗法.中国中医药出版社,1995 年版.
55 廖军祥,谢仁敷,郭惟.补肾活血方对骨髓造血作用的病理及电镜观察.实用中西医结合杂志,1991,4(12);731～732.
56 李楠 , 戴锡孟 . 补肾方药对骨髓造血影响的实验研究进展 . 天津中医学院学报,1994,(4);44～46.
57 李楠,戴锡孟.补肾方药对骨髓造血影响的实验研究进展.天津中医学院学报, 1994, (4); 44～46.
58 储真真,陈信义.化疗后骨髓抑制中医临床理论探讨与防治对策.中华中医药学报,2004,11(6);5-8.
59 田振典,李苏宣,阚全程等.归脾汤加减干扰化疗后白细胞下降序贯试验.河南医科大学学报,1996,31(2);80～81.
60 吴荻,张越,刘敬伟等.补气养血法治疗非霍奇金淋巴瘤化疗致白细胞减少 46 例.吉林中医药,2002,22(1);17.
61 刘振学.当归补血汤对减轻放化疗骨髓抑制的初步观察.实用中西医结合杂志, 1993,(3);166.
62 张子丽,刘影,刘子厚.八珍汤加味治疗放疗及化疗所致的白细胞减少症.实用肿瘤学杂,1996,10(3);43～44.
63 李月华,朱海婴,叶启霞等.气血葆口服液对放化疗毒性作用的影响.中国中医药信息杂志,1996,3(7);13.
64 苗文红.补肾健脾法治疗肿瘤放化疗所致的骨髓抑制 98 例.陕西中医,2000,21(7);289.
65 王迎红,王怀璋,余永虎.中药对癌证化疗后骨髓保护作用的临床研究.河南中医药学刊,2000,15(6);64～65.
66 王玉华,曲士杰,郭郁等.扶正培本法防治肿瘤化疗后白细胞血小板减少.中国民间疗法, 2001,9(11);48.
67 李永安,李国庆.化疗中气阴两虚证的辨证治疗.四川中医,2002,20(1);14.
68 孙隆生,朱新勇,于秋华等.癌血生合剂纠正肿瘤放化疗骨髓抑制100例分析肿瘤防治究, 1994,21(3);190～191.
66 林能明,陈晓钟,郑晓等.生白宝口服液治疗恶性肿瘤放化疗引起的白细胞减少症的临床观察.肿瘤防治研究,1995,22(6);392.
70 李明众,赵东利,王书文.复方皂矾丸对恶性肿瘤病人放化疗骨髓保护及升白作用.西药学杂志,1998,13(2);80～81.
71 李明众,赵东利,王书文.复方皂矾丸对恶性肿瘤病人放化疗骨髓保护及升白作用.西北药学杂志,1998,13(2);80～81.
72 宋海洪,陈泽涛,齐元意等.参莲温胆合剂治疗化疗所致的白细胞和血小板减少的临床观察和实验研究.上海中医杂志,1997,10(2);13.
73 赵国华,张新,戴卫东.半夏泻心汤在食管癌化疗中减毒作用的临床观察.中医研究,1996,9(2);40～41.
74 冯璞,赵扬,罗崇念.补肾合剂对免疫缺陷小鼠造血功能的影响.中草药,1998,29(11);752～754.
75 吴志奎,姜葆华,李永军.肾生髓理论的现代研究.中医杂志,1999,40(10);626～628.
76 李楠,戴锡孟.补肾方药对骨髓造血影响的实验研究进展.天津中医学院学报, 1994, (4); 44～46.
77 李佩文,赵建成.恶性肿瘤并发症实用疗法.中国中医药出版社.1995 年版.
78 冯璞,赵扬,罗崇念.补肾合剂对免疫缺陷小鼠造血功能的影响.中草药, 1998, 29 (11); 752～754.
79 邓成珊等.当代中西医结合血液病学.中医医药科技出版社,1997,362.
80 李美芬等.AM 促进小鼠粒系造血.湖南医科大学学报,1991,16(2);135-136.
81 李仪奎,姜名瑛等.中药药理学.北京中医药出版社,1992;183-187.
82 刘星皆,喻正坤.AM 成分和药理活性研究进展.上海医药,1995,16(20);23.
83 潘敏求,主编.中华肿瘤治疗大全.石家庄,河北科技出版社,1996,53.
84 刘辉,李金荣,胡传真.AM 对磷癌细胞株 GNM 荷瘤鼠的免疫增强及抑瘤作用的研究.口腔医学,1999,19(2);60-61.
85 王德昌等.黄芪多糖 FB 对人血淋巴细胞免疫功能的影响[J].中华肿瘤杂志, 1998, 11 (3);180.
86 黄兆生.中药学人民卫生出版社,2004,454.
87 李仪奎,姜名瑛等.中药药理学.北京中医药出版社,1992;183-187.
88 黄泌.免疫药物学[M].上海:上海科学技术出版社,1986,142-176.
89 黄兆生.中药学人民卫生出版社,2004,454.
90 李美芬等.黄芪促进小鼠粒系造血实验研究.湖南医科大学学报,1991,16(2);135-136.
91 王德昌等.黄芪多糖 FB 对人血淋巴细胞免疫功能的影响.中华肿瘤杂志,1998,11(3);180.
92 黄兆生.中药学人民卫生出版社,2004,454.
93 李仪奎,姜名瑛等.中药药理学.北京中医药出版社,1992,183-187.
94 黄兆生.中药学人民卫生出版社,2004,454.
1 裴雪涛.加强造血调控的基础与临床研究.中华血液学杂志.1998, 19(6); 283-284.
2 Broxmeyer HE, Kim CH. Regulation of hematopoiesis in a sea of chemokine family member with a Plethora of redundant activities EXP Hematol, 1999, 27; 113-1123.
3 Ziegler BL, Buhring HJ, Schedings, et al. cytokine reponses of hematopoietic Progenitor cells. in: Educational Program book. 98 ISH-EHA combined haemato Logu congress. Amsterdam, 1958, 51-57.
4 杨藻宸主编.医用药理学.第 3 版,北京:人民卫生出版社,1994,1023.
5 彭登慧,谢仁敷,田丰.补肾中药对注射环磷酰胺小鼠骨髓微循环障碍的影响.中西医结合杂志,1983,3(5);292.
6 TO LB, Haylock ON, Simmons PJ, ex ell. The biology and chinical uses of blood stem cells Blood, 1997, 89; 2233-2258.
7 TO LB, Haylock ON, Simmons PJ, ex ell. The biology and chinical uses of blood stem cells Blood, 1997, 89; 2233-2258.
8 李晓,浦汉,周艳贞等.细胞毒药物对急性白血病原位凋亡的诱导作用.上海第二医科大学学报,2001,21(1);57-59,87.
9 Williams GT, Smithc. Molecular regulation of apoptosis genetil controls on Celldeath.Cell, 1993:74.
10 魏晓超,蔺新力,王新娟.肿瘤坏死因子相关的凋亡诱导及其与肿瘤治疗前景,生理学进展,2001,32(1);8-22.
11 Bodine Dm, Crosier PS, Clark SC. Effects of hematopoietic growth fastors on the survival of primitive stem ells in Lignid suspension culture. Blood, 1991, 78; 914.
12 Macijewsk JP, Selleric, Sato T, et al. Nitrie oxide suppression of human hematopoiesis in vitro Contribution to inhibitory action of inter feron-gamma and tumor necrosis factor alpla. J clin invest, 1995, 96;1085.
13 Sugahara H. Ishikawa J. Hashimotok, et al. induction of programmed cell death in human hematopoitic cell lines by fibronectin via its interaction with wery late antigen 5. JEXP med, 1994, 179; 1757.
14 杨志祥,麋漫天.造血分化与细胞周期调控.国外医学输血及血液学分册,1999, 22 (2);
101-103.
15 霍中和,王喜忠,丁明孝主编.细胞生命学.北京:高等教育出版社,1995,8; 357-411.
16 Jacks T and Weinberg RA. The expanding role off cell cycle regulators Scienlce, 1998, 280; 1035.
17 董凌莉,刘文励.细胞粘附与细胞周期调控.中华血液学杂志,2000,7(21); 389-390.
18 曾益新主编.肿瘤学.北京:人民卫生出版社,1999,11;97-118.
19 吴祖泽,沈世人,朱爱武等.外周血造血干细胞性能和移植的实验研究.中国科学, 1980,(12);1228.
20 王声远,李真,马宜行.造血干细胞的研究Ⅱ.骨髓冻存后干细胞活力的测定.中华血液学杂志, 1981,2;133.
21 Civincl, Strausst LC, Brouall C, et al. Antigenic analysis of hematopoiesis, Ⅲ. A hemapoietic progeniceir cell surface antigen defined by a monoclonal antibody raised against KG-la cells. J lmmunol, 1984, 133; 157-165.
22 Bender JG, unverzagek, WalkweDE, et al. Phenotypic and characterization of CD34+ cells from normal human bone marron, cord blood, peripheral blood, and mobilized peripheral blood from Patients undergoing antologous stem cell transplantation. Clin Immunopath, 1994, 70; 10-18.
23 马思普,刘秀玲,韩颖等.低分子硫酸葡聚糖对 Beagle 狗外周血细胞动员作用的研究.中华血液学杂志,1996,17;251.
24 吴祖泽,贺福初,裴雪涛主编.造血调控.上海:上海医学大学出版社,2000,9;79-110.
25 陈彤,李佩,谢毅.造血干细胞表面的粘附分子及其在干细胞移植中的作用. 国外医学输血及血液学分册,2000,23(2);19-21.
26 To LB et al. The biology and chinieal uses of blood stem cells. Blood, 1997; 89:2233-2258.
27 Simmous PJ et al. Potential adhesion mechanisms for localization of heamopoieeic progenitors to bone marrow stroma. Lenkemi lymphoma, 1994, 12; 353-363.
28 Turner ML. Regulation of hematopoietic progenitor cell migration. Mobilization and homing stem cells, 1994, 12; 227-229.
29 Tavassolim & hard CL. Molelular basis of homing of intravenously transplant stem cells. Blood. 1990, 76;1059-1070.
30 黄文荣,张伯龙,达万明.粘附分子与造血干细胞移植.国外医学输血及血液学分册, 2000, 23(2);1-4.
31 Jacobson K et al. Adhesion receptors on bone marrow stroma cells in vivo expression of vascular cell adhesion molecule-l and by reticular cells and sinusoidal endothelium in normal and irradiated mice. Blood, 1996, 87; 73-82.
32 Papay dnnopoulot T & Nakamoto B. peripheralisation of hemopoietic progenitor in primates treated with auti-VLA-4 intergrin. Pro. Nat Acad scien USA, 1993, 90; 9374 -9378.
33 Janowska- wieczorek A et al. Growth factor and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. Blood, 1999, 93; 3379-3390.
34 Chabanon C et al. patient conclition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colong-stimulating factor. J Hem atother, 1995, 4; 171-175.
35 李战强,白庆咸,杨平地.趋化因子—基质细胞源性因子-1 与造血. 国外医学输血及血液学分册,1998,21(3); 156-158.
36 Mielcarek M, Reems J, Torok SB. Extrinsic control of stem cell fatepractical considerations. Stem cells, 1997; 15(suppl1): 229.
37 Joshi SS, Counolly J mann SL, et al. Altered in Vitro behavior of butanol-modified bone marrow. Cells, Exp Hematol, 1995; 23: 1284.
38 Hirsch E, lglesias A, Potocnik AJ, et al. Impaired migration but out differentiation of haematopoietic stem cells in the absence of βintegrins. Natnre, 1996, 380: [7] .
39 Turner ML, Sweeten ham JW. Haemopoietic Progenitor homing and mobilization. Br Haematol, 1996, 94: 592.
40 Wineman J, moorek, lemischka I, et al. Functinal heterogeneity of the hematopoietic microenviron ment; rare Stromal elements maintain long-term repopulating seem cells. Blood, 1996, 87; 4082-4090.
41达万明.MaDFF.骨髓移植后造血微环境重建的研究.中华血液学杂志,1987,(8);18-20.
42达万明,裴雪涛主编.外周血干细胞移植.北京:人民卫生出版社,2000,09;265-273.
43项莺松,梁志华.造血干细胞移植研究中的美学观.医学与哲学,1999,20(7):63-64.
44 林旭滨 , 刘天洁 , 陈运贤 . 造血基质细胞和造血干细胞移植 . 国外医学内科学分册,2001,28(3);112-115.
45刘天洁,林旭滨,陈运贤.基质细胞与造血干细胞移植后的造血重建.中国病理生理杂志,2000,16(5);474-477.
46Knospe WH, Husseini SG, Zipori, et al. Hematopoiesis on cellulose ester membranes. Ⅷ.A combinntion of cloned stromal cells is needed to establish a hematopoietic microenvironment supportive of trilineal hematopoiesis [J]. EXP Hematol, 1993,21;257.
47孙岚,刘文励.VEGF 及其受体调节造血细胞生长的作用.临床血液学杂志.2000, 13(6); 284-285.
48吴岩,祝彼得.内皮细胞与造血调控的研究.国外医学输血及血液学分册,2001,24(1); 9-13.
49滕小伟,赵佼,谭文松.内皮细胞在调控造血中的作用.国外医学输血及血液学分册,2001,24(1); 16-18.
50Klein G. The extracell ular matrix of the hematopoietic miroenviroment[J]. Experientia, 1995, 51;914.
51成军.细胞外基质的分子生物学与临床疾病.北京:北京医科大学出版社,1999,6;196-204.
52Suito M. Recent trends in research on differentiation of hematopoietic cells and lymphokines(hemopoietins). Hum cell ,1992,5;54.
53达万明,裴雪涛主编.外周血干细胞移植.北京:人民卫生出版社,2000,9;5-6.
54Rose-John S, Heinrich PC. Soluble releptors for cytokines and growth factors: generation and biological function. Biochem J, 1994, 300; 281.
55Herington AC, Ymer S, Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J clin lnvest, 1996; 77:1817.
56Spriggs MK, Hruby DE, maliszewski CR, et al. vaccinia and viruses encode anovel secreted interleukin-l-binding protein. cell, 1992, 71;145.
57Yamazaki K, Yamada E, Kanaji Y, et al. interleukin-6 (IL-6) inhibite theroid function inthe present of soluble IL-6 receptor in cnlture human thyoid follicles. Endocrinology, 1996, 137; 4857.
58吴祖泽,贺福初,裴雪涛主编.造血调控.上海:上海医科大学出版社, 2000,9;128-153.
59Bergelson S, Socolovsky M, Hsiao JG, et al. Tyrosine residues within the intercellular domain of the erythropoietin receptor mediate activation of AP-1 trans cription factors. J Boil chem, 1998,273;2396.
60Hunter T. protein kinases and phosphateses: the Yin and Yang of protein phosporylatio and signaling. Cell, 1995, 80;225.
61Pelech SL, Sanghera JS. mitogen-activated protein kinases versatile transducers for cell signaling. TLBS, 1992,17;233.
62Bumer KJ, Johnson GL. diversity in function and regulation of MAP kinase pathway. trenls.Biochem Sic, 1995,19; 236.
63刘永学,贺福初,吴祖泽.生长因子及细胞因子的两条重要信息传导通路.生物化学与生物物理进展,1996,23;4.
64Levg DE. The house that JAK/STAT built. Cytokine Growth factor Rev, 1997, 8;81.
65Sakatsllme M, Stancato LF, David M, et al. interferon gamma sctivation of Raf-l is Jak1-dependent and p21ras independent.J Bool Chem, 1998, 273; 3021.
66Malarkey K, Belham CM, Paul A, et al. the regulation of tyrosine signaing pathways by factor and G-protein-Couplesd receptors. Biochem J, 1995, 309; 361.
67Bredt S, Snyder SH. Nitric oxide: A Physiolongic messenger molecule. Annu Rew Biochem, 1994, 63; 175-195.
68Fukuto JM, Chandhuri G. inhibition of constitutive and inducible NOS: Potential selective inhibition. Annu Rew Pharmacol Toxicol, 1995; 35:165-194.
69Cross SS. Wolin MS. Nitric oxide: pathophysiologica mechanisms. Annu Rew phsiol, 1995, 57; 737-769.
70肖学艺,吕国蔚.一氧化氮的生物学特征和作用.首都医科大学学报,1999,20(4);311-314.
71李中东,晏家益,吴群林.一氧化氮对血液系统的调节作用.国外医学输血及血液学分册,1999,22(4);254-256.
72Kamijo R, Harada H, Matsuyama T, et al. Reguirement for transcription factor IRF-lin NO synthase induction macrophages. Science , 1994, 263; 1612-1615.
73Macijewsk JP, selleric, saato, et al. Nitric oxide suppression of human hematopoiesisin Vitro contribution to inhibitory action of interferon-gamma and tumor necrosis factor alpha. J clin invest, 1995, 96; 1085.
74 Rafferty SP. Domachowske JB, malech HL.Inhibitorm of hemoglobin expression by hetorolognos peoduction of nice oxide synthase in the K562 erythroleukemic cell line. Blood, 1996, 88; 1070-1078.
75Forrester K, Ambs S. Lupold SE. et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric synthase expression by Wild-type p53. Proc Natl Acad sci USA, 1996, 93; 2442-2447.
76罗高光,徐秋萍.一氧化氮对细胞凋亡的影响[J].国外医学,临床生物化学与检验学分册,1997,18(40);145-146.
77于文强,孙秉中.一氧化氮与造血调控.中华血液学杂志,1998,19(10);557-559.
78张彩,田志刚.肿瘤免疫逃逸机制的研究进展.国外医学肿瘤学分册,2000,27(2);77-78.
79汤钊猷主编.现代肿瘤学.第二版,上海:上海医科大学出版社,2000;9:239-293
80王振义,陈竺主编.肿瘤的诱导分化和调亡疗法.上海:上海科技出版社,1998;1-10.
81张劲旅,张锦堃.人血树突状细胞研究进展.国外医学输血及血液学分册, 1998, 21 (5); 302-305.
82孙恺,张茂宏,田志刚等.LAK 细胞和活化 NK 细胞对小鼠骨髓造血功能影响的实验研究.中华血液学杂志,1999,20(8);405-408.
83 郭 宝 刚 , 田 志 刚 .NK 细 胞 亚 群 及 其 对 造 血 的 调 节 效 应 . 国 外 医 学 肿 瘤 学 分册,1997,24(3);139-140.
1 李佩文.中西医结合临床肿瘤学.中国中医药出版社,1996,244.
2 田卫卫,王庆苗.恶性肿瘤化疗后骨髓抑制的病机及临床治疗探讨.河北中医, 2000,22(10);791～792.
3 扬晓峰,王锐,邱根全.孙喜才治疗肿瘤放化疗后白细胞减少症经验拾零.山西中医, 2000, 10(16);7～8.
4 田振典,李苏宣,阚全程等.归脾汤加减干扰化疗后白细胞下降序贯试验.河南医科大学学报,1996,31(2);80～81.
5 刘嵚,姚力峰.辨证论治化疗后白细胞减少症 32 例疗效观察.中国中医药信息杂志,1998,5(7);33～34.
6 吴荻,张越,刘敬伟.补气养血法治疗非霍奇金淋巴瘤化疗致白细胞减少 46 例.吉林中医药,2002,22(1);17.
7 蔡宇,赵益亚,金君梅.化疗所致骨髓抑制的中医药辨证.吉林中医药,1998,(1);1.
8 田振典,李苏宣,阚全程等.归脾汤加减干扰化疗后白细胞下降序贯试验.河南医科大学学报,1996,31(2);80～81.
9 吴荻,张越,刘敬伟.补气养血法治疗非霍奇金淋巴瘤化疗致白细胞减少 46 例.吉林中医药,2002,22(1);17.
10 刘振学.当归补血汤对减轻放化疗骨髓抑制的初步观察.实用中西医结合杂志, 1993, (3); 166.
11 张子丽,刘影,刘子厚.八珍汤加味治疗放疗及化疗所致的白细胞减少症.实用肿瘤学杂,1996,10(3);43～44.
12 李月华,朱海婴,叶启霞等.气血葆口服液对放化疗毒性作用的影响.中国中医药信息杂志,1996,3(7);13.
13 李明众,赵东利,王书文.复方皂矾丸对恶性肿瘤病人放化疗骨髓保护及升白作用.西北药学杂志,1998,13(2);80～81.
14 宋海洪,陈泽涛,齐元意等.参莲温胆合剂治疗化疗所致的白细胞和血小板减少的临床观察和实验研究.上海中医杂志,1997,10(2);13.
15 赵国华,张新,戴卫东.半夏泻心汤在食管癌化疗中减毒作用的临床观察.中医研究,1996,9(2);40～41.
16 苗文红.补肾健脾法治疗肿瘤放化疗所致的骨髓抑制 98 例.陕西中医,2000,21(7);289.
17 王玉华,曲士杰,郭郁.扶正培本法防治肿瘤化疗后白细胞血小板减少.中国民间疗法,2001,21(7);289.
18 李永安,李国庆.化疗中气阴两虚证的辨证治疗.四川中医,2002,20(1);14.
19 林能明,陈晓钟,郑晓等.生白宝口服液治疗恶性肿瘤放化疗引起的白细胞减少症的临床观察.肿瘤防治研究, 1995,22(6);392.
20 齐元富,钱伯文.肿瘤血瘀证及活血化瘀治疗的现代研究进展.中医杂志,1993,34 (6); 370～373.
21 刘承煌.胸部恶性肿瘤患者的甲皱微循环表现.中华肿瘤杂志,1986,8(4);250 .
22 施永德.恶性肿瘤病人的紫舌和血液流变学分析.中华肿瘤杂志,1981,3(3);222 .
23 王笑天.癌证患者的瘀血证与血液高凝状态的研究.中国中西医结合学会活血化瘀研究学会编.血液证与活血化瘀研究.北京:学苑出版社,1990,260.
24 齐元富,钱伯文.肿瘤血瘀证及活血化瘀治疗的现代研究进展.中医杂志,1993,34 (6); 370～373.
25 纪树国.肺癌患者凝血状态的现象.肿瘤防治研究,1990,17(2);82.
26 陈泽霖.恶性肿瘤青紫舌病人的血液流变学和微循环观察.吉林中医药,1984,(3);27.
27 李佩文.中西医结合临床肿瘤学.中国中医药出版社,1996,244.
28 马振亚.中药方剂免疫机理研究.西安:陕西科技出版社,1986,14.
29 蔡宇,赵益亚,金君梅.化疗所致骨髓抑制的中医药辨证.吉林中医药,1998,(1);1.
30 李佩文.中西医结合临床肿瘤学.中国中医药出版社,1996;244.
31 王玉华,曲士杰,郭郁.扶正培本法防治肿瘤化疗后白细胞血小板减少.中国民间疗法, 2001,21(7);289.
32 赵省,赵宏亮,宋长河.丹参防治肿瘤化疗所致骨髓抑制的研究.河南肿瘤学杂志,1994, 7(2);134～135.
33 刘俊杰,周成运.苦参素注射液治疗 56 例肿瘤化疗后白细胞减少症.肿瘤学杂志, 2005, 11(2):155-156.
34 李佩文.中医药治疗化疗毒副反应的现状与展望.中国中医药信息杂志,1996,3(1);22.
35 田振典,李苏宣,阚全程等.归脾汤加减干扰化疗后白细胞下降序贯试验.河南医科大学学报,1996,31(2);80～81
36 刘振学.当归补血汤对减轻放化疗骨髓抑制的初步观察.实用中西医结合杂志,1993, (3); 166
37 张子丽,刘影,刘子厚.八珍汤加味治疗放疗及化疗所致的白细胞减少症.实用肿瘤学杂, 1996,10(3);43～44.
38 竹川佳宏.汉方と最新治疗.2001,10(2);185～188.
39 苗文红.补肾健脾法治疗肿瘤放化疗所致的骨髓抑制 98 例.陕西中医,2000,21(7);289.
40 刘少翔,陈志峰,胡海山.中医药与磁疗防治放化疗后副作用的临床研究.辽宁中医杂志, 1995,22(2);64.
41 王迎红,王怀璋,余永虎.中药对癌证化疗后骨髓保护作用的临床研究.河南中医药学刊, 2000,15(6);64～65.
42 王玉华,曲士杰,郭郁.扶正培本法防治肿瘤化疗后白细胞血小板减少.中国民间疗法, 2001,21(7);289.
43 李明众,赵东利,王书文.复方皂矾丸对恶性肿瘤病人放化疗骨髓保护及升白作用.西北药学杂志,1998,13(2);80～81.
44 张蕾.升白汤合复方皂矾丸治疗化疗后白细胞减少80例.现代中西医结合杂志,2002, 11 (11);1023.
45 文灿途,缪英年,陈茂潮.健脾益肾饮治疗化疗后白细胞减少症.湖北中医杂志,2002,24 (1);28.
46 张宏,李国康.增髓汤对乳腺癌术后化疗改善骨髓抑制的研究.实用中医杂志,2005,21 (13):1481-1482.
47 陈闯.化疗后白细胞减少症的疗效分析.甘肃中医,1999,12(3);22～23.
48 孙隆生,朱新勇,于秋华.癌血生合剂纠正肿瘤放化疗骨髓抑制 100 例分析.肿瘤防治研究, 1994,21(3);190～191.
49 杨泽江,李志革,黄秉琰.生血宝防治化疗所致骨髓抑制 13 例临床观察.湖南中医杂志, 1997,13(3);20～22.
50 林能明,陈晓钟,郑晓等.生白宝口服液治疗恶性肿瘤放化疗引起的白细胞减少症的临床观察.肿瘤防治研究,1995,22(6);392.
51 李月华,朱海婴,叶启霞等.气血葆口服液对放化疗毒性作用的影响.中国中医药信息杂志,1996,3(7);13.
52 宋海洪,陈泽涛,齐元意等.参莲温胆合剂治疗化疗所致的白细胞和血小板减少的临床观察和实验研究.上海中医杂志,1997,10(2);13.
53 赵国华,张新,戴卫东.半夏泻心汤在食管癌化疗中减毒作用的临床观察.中医研究, 1996, 9(2);40～41.
54 刘嵚,姚力峰.辨证论治化疗后白细胞减少症32例疗效观察.中国中医药信息杂志,1998, 5(7);33～34.
55 吴荻,张越,刘敬伟.补气养血法治疗非霍奇金淋巴瘤化疗致白细胞减少 46 例.吉林中医药,2002,22(1);17.
56 李永安,李国庆.化疗中气阴两虚证的辨证治疗.四川中医,2002,20(1);14.
57 吴德峰.六神散治疗化疗后白细胞减少症 50 例.江苏中医药,2002,23(10);27.
58 朱俐俐,郭立新.益气养阴法治疗化疗后白细胞减少32例.江苏中医药,2002,23(1);22-23.
59 李松林.参麦针合中汤药防治肿瘤化疗后白细胞减少症 39 例.陕西中药,2003,24 (12); 1064-1065.
60 何文华,杨维春,张宏江,等.地榆升白片加粒细胞集落刺激因子预防化疗后骨髓抑制临床观察.中国中医药信息杂志,2005,12(11);77.
61 胡欣,李戈,王子鑫等.穴注配合参附注射液治疗肿瘤化疗后白细胞减少症 30 例.实用中医内科杂志,2006,20(3);341-342.
62 唐新星.中药穴位注射配合内服治疗化疗后白细胞减少症 24 例.安徽中医临床杂志, 2001,13(1);39-40.
63 邢海平,王天昌,王俊生.博生癌宁透皮药贴对恶性肿瘤化疗后骨髓抑制的保护作用.中医研究,1998,11(3);24～25.
64 冯璞,赵扬,罗崇念.补肾合剂对免疫缺陷小鼠造血功能的影响.中草药,1998,29(11); 752～754.
65 李振波,丘和明,刘国普.清毒饮和养正片对环磷酰安所致的造血抑制小鼠粒系造血的影响.广州中医药大学学报,1999,16(1);34～37.
66 廖军祥,谢仁敷,郭惟.补肾活血方对骨髓造血作用的病理及电镜观察.实用中西医结合杂志,1991,4(12);731～732.
67 吴志奎,姜葆华,李永军.肾生髓理论的现代研究.中医杂志,1999,40(10);626～628.
68 竹川佳宏.汉方と最新治疗,2001,10(2);185～188.
69 北原正和.汉方と最新治疗, 2001,10(2);189～192.
2 Pizzo PA, Hathorn Jw, Hiemenz, et al.A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med, 1987, 315; 552-8.
3 Talcott JA, Siegel RD , Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutopenia: A prospective two-center validation of a prediction rule. J Clin Oncol.1992 .10:316-22, 1992
4 RechtA, Come SE, Gelman RS, Goldstein.m, Tishler S, Gotes Sm, Abner AL, Vicini FA, SilverB, Connolly JL, Schnitt SJ, Coloman NC, Harris JR. Integration of conservation of conservative surgery, radiotherapy and chemotherapy for the treament of early stage, node positive breast cancer, sequencing timing and outcome. [J]Clin Oncol, 1991.9; 1662.
5 Fyles A, Keane TJ, Barton M, Simmj.The effect of treament duration in the local control of cervix cancer. Radiother Oncol .1992.25; 273 1992
6 Cox JD, Dajak TF, Asbells, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M 3rd: Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unrecases from 3 Radiation therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys.1993.27; 493.
7 Wang CC, Efird JT. Dose prolonged treament course adversely affect local control of carcinoma of the larynx.Int J Radiat Oncol Biol Phys,1994,29;657.
8 Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy Int J Radiat Oncol Biol Phys, 1992, 23; 457.
9 Ma Cormick B. Radition therapy for breast cancer. Curr Opin Oncol, 1993,.5; 976.
10 Turrisi AT 3rd. Platnum combined with radiation therapy in small cell lung cancer: Focusing like a laser beam on crucial issues. Semin Onco, 1994, 21; 34
11 Cullen MH.Trials of radiotherapy versus chemotherapy plus redical radiotherapy in non-small cell lung cancer. Semin Oncol, 1994, 21; 34,
12 Taylor SG. Chemotherapy in the multimodality treament of head and neck cancer, in Kagan AR, Miles J (eds): Head and neck Oncology: Clinical Management.Elmsford, NY, Pergamon, 1989, p166.
13 Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophsgus. N Engl J Med1992,326;1593,
14 Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Adjuvant therapy of resected andenocarcinoma of the pancreas.Int J Radiat Oncol Biol Phy1991,21;1137.
15 O’Connell MJ, Mayer RJ, Gunderson JA, Wieand HS,Krook JE, Macdonald JS, Haller DG, Mayer RJ, underson LL, Rich TA.Improving adjuvant therapy for rectal cancer by combiling protracted-infusion fluorouracil with radiation therapy after curative surgey.N’sEngl J Med1994, 331:502, 1994.
16 RechtA, Come SE, Gelman RS, Goldstein.m, Tishler S, Gotes Sm, Abner AL, Vicini FA, SilverB, Connolly JL, Schnitt SJ, Coloman NC, Harris JR. Integration of conservation of conservative surgery, radiotherapy and chemotherapy for the treament of early stage, node positive breast cancer, sequencing timing and outcome. J Clin Oncol 1991, 9; 1662.
17 Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Homing SJ.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin disease: A preliminary report. J Clin Oncol, 1995, 13; 1080.
18 Grawford J,Ozer H,Stoller R,et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med, 1991, 325; 164.
19 候俊卿,段玉龙,史中州.胚胎胸腺移植在恶性肿瘤治疗中的应用.中国肿瘤临床康复1996,2(4);41-42.
20 Knutson S In vitro grouth of granulocyte colonies from circulating cells in cord biood, 1947, 43; 357.
21刘欣,孙自敏.静脉丙种球蛋白(IVIG)预防恶性血液病化疗后感染的临床评价(附46例报告).哈尔滨药,2000,20(1);1.
22 Dicke KA, Spitzer G, Evaluation of the use of high dose cytoreduction with auto logo us marrow rescue in various malignancies [J].Transplantation,1986,41(1);4—20.
23 哈森,肖镇.自体骨髓移植在实体瘤治疗中的应用研究.A cta Acad Med N eiM ongol Dec.2002, 24(4);248.
24 Hanun YA. Apoptosis and the dilemma of cancer chemotherapy [J] Blood, 1997, 89(6); 1845-1853.
25 Hanun YA. Apoptosis and the dilemma of cancer chemotherapy [J] .Blood, 1997, 89(6); 1845-1853.
26 Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis [J]. Annu Rev Physion, 1998, 60; 619-642.
27 王振义,陈竺主编.肿瘤的诱导分化和凋亡疗法.上海科学技术出版社出版第 1 版.1998, 158-160.
28 田卫卫.化瘀补虚方改善化疗后小鼠骨髓抑制机制研究.成都中医药大学博士学位论文,2003.
29 Crawford J, Ozer H, stoller R, et al. Reduction by granulocy t colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med, 1991, 325;164.
30 哈敏文,何安光.黄芪合剂防治化疗性骨髓抑制的实验研究.中国医科大学学报, 1997, 26(5);449-452.
31 Jerome EG,Loretta MI.Chemotherapy-Induced Anemia in Adults.Incidence and Treatment.J Natl Cancer Inst,1999,91;1616～1634.
32 Gale RP. Auto logo us bone marrow transplantation in patients with cancer [J]. JAMA,1980; 243(6):540-542.
33 孙燕主编.内科肿瘤学.人民卫生出版社,265-266.
34 Blay JY, Chauvin Fet al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Dncol, 1996, 14:636-643.
35 Michael Mac et al. Radiotherapy—associated neutopenia and thrombocy topenia: Analysis of risk factors and development of a predictive model. Blood, 1997, 89; 2303-2310.
36 郭艳霞,于成宝,刘秋菊.化疗后骨髓抑制预测性模型的建立.吉林医学, 2005, 26(12); 1257-1259.
37 Michael Mac et al. Radiotherapy—associated neutopenia and thrombocy topenia: Analysis of risk factors and development of a predictive model. Blood, 1997, 89; 2303-2310.
38 Watkins SM. Predicting neutropenia after chemotherapy for lymphoma. Leuk Lymphoma, 1994, 9; 107-109.
39 Kitay—Cohen Y,Lishner M,she lef A,et al.Bone marrow involvement, in intensively treated patient with intermediate grade non-Hodgkin’s lymphoma, is a risk factor for granulocy topenia and fever. Leuk Lymphoma. 1996, 20; 333-336.
40 Silber JH, Fridman M, Dipaola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol, 1998, 16; 2392-2400.
41 Eric Voog et al. Factors that predict chemotherapy-induced myelosuppression in lymphoma Patients: Role of the tumor necrosis factor ligand-receptor system. J Clin Oncol, 2003, 18; 325-331.
42 刘秋菊,姜玉珍,贾娇源.化放疗后骨髓抑制危险因素分析.江西医学院学报, 2005,45 (3); 48-50.
43 韩瑞刚,彭瑞云.电离辐射对骨髓损伤的研究进展.中华放射医学与防护杂志, 2005, 25 (6);586～588.
44 Cella D, Dobrez D,Giaspy J.Control of cancer related anemia with erythropoietin agents:a review of evidence for improved quality of life and clinical outcomes.Ann Oncol, 2003, 14 (4);511～519.
45 Cohen HJ.Geriatric principles of treatment applied to medical oncology.an overview.Semin Oncol,1995,22(suppl 1);1～2.
46 Vose JM.Cytokineuse in the older patient.Semin Oncol,1995,22(suppl 1);6～8.
47 Cella D.Factors influencing quality of life in cancer patients Anemia and fatigue.Semin Oncol,1988,2s;43～46.
48 Loretta MItri.Ortimal Hemoglobin level for cancer patients.semin oncol,2000,27 (supple 4); 12～15.
49 Winninghan ML,Nail LM,Burke MB,et al.Fatigue and the cancer experience the state of the knowledge.Oncol Nurs Forum,1994,21;23～36.
50 Krishnasamy M.Social support and the patient with cancer:a consideration of theliterature .Adv Nurs,1999,23(4);757～762.
51 Cawford J, Ozer H, Stoller R, et al. Reduction by granulocyt colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med, 1991, 325; 164.
52 Longo DL, Devita VT, Jaffe ES, et al. Toxicities of therapy for aggressive lymphomas. Devita VT Jr, Cancer Principles&Practice of Oncology. 4th Edtition JB Lippincott, Philadelphia, 1993.
53 王笑天.癌证患者的瘀血证与血液高凝状态的研究.中国中西医结合学会活 血化瘀研究学会编.血液证与活血化瘀研究.北京.学苑出版社,1990;260.
54 李佩文,赵建成.恶性肿瘤并发症实用疗法.中国中医药出版社,1995 年版.
55 廖军祥,谢仁敷,郭惟.补肾活血方对骨髓造血作用的病理及电镜观察.实用中西医结合杂志,1991,4(12);731～732.
56 李楠 , 戴锡孟 . 补肾方药对骨髓造血影响的实验研究进展 . 天津中医学院学报,1994,(4);44～46.
57 李楠,戴锡孟.补肾方药对骨髓造血影响的实验研究进展.天津中医学院学报, 1994, (4); 44～46.
58 储真真,陈信义.化疗后骨髓抑制中医临床理论探讨与防治对策.中华中医药学报,2004,11(6);5-8.
59 田振典,李苏宣,阚全程等.归脾汤加减干扰化疗后白细胞下降序贯试验.河南医科大学学报,1996,31(2);80～81.
60 吴荻,张越,刘敬伟等.补气养血法治疗非霍奇金淋巴瘤化疗致白细胞减少 46 例.吉林中医药,2002,22(1);17.
61 刘振学.当归补血汤对减轻放化疗骨髓抑制的初步观察.实用中西医结合杂志, 1993,(3);166.
62 张子丽,刘影,刘子厚.八珍汤加味治疗放疗及化疗所致的白细胞减少症.实用肿瘤学杂,1996,10(3);43～44.
63 李月华,朱海婴,叶启霞等.气血葆口服液对放化疗毒性作用的影响.中国中医药信息杂志,1996,3(7);13.
64 苗文红.补肾健脾法治疗肿瘤放化疗所致的骨髓抑制 98 例.陕西中医,2000,21(7);289.
65 王迎红,王怀璋,余永虎.中药对癌证化疗后骨髓保护作用的临床研究.河南中医药学刊,2000,15(6);64～65.
66 王玉华,曲士杰,郭郁等.扶正培本法防治肿瘤化疗后白细胞血小板减少.中国民间疗法, 2001,9(11);48.
67 李永安,李国庆.化疗中气阴两虚证的辨证治疗.四川中医,2002,20(1);14.
68 孙隆生,朱新勇,于秋华等.癌血生合剂纠正肿瘤放化疗骨髓抑制100例分析肿瘤防治究, 1994,21(3);190～191.
66 林能明,陈晓钟,郑晓等.生白宝口服液治疗恶性肿瘤放化疗引起的白细胞减少症的临床观察.肿瘤防治研究,1995,22(6);392.
70 李明众,赵东利,王书文.复方皂矾丸对恶性肿瘤病人放化疗骨髓保护及升白作用.西药学杂志,1998,13(2);80～81.
71 李明众,赵东利,王书文.复方皂矾丸对恶性肿瘤病人放化疗骨髓保护及升白作用.西北药学杂志,1998,13(2);80～81.
72 宋海洪,陈泽涛,齐元意等.参莲温胆合剂治疗化疗所致的白细胞和血小板减少的临床观察和实验研究.上海中医杂志,1997,10(2);13.
73 赵国华,张新,戴卫东.半夏泻心汤在食管癌化疗中减毒作用的临床观察.中医研究,1996,9(2);40～41.
74 冯璞,赵扬,罗崇念.补肾合剂对免疫缺陷小鼠造血功能的影响.中草药,1998,29(11);752～754.
75 吴志奎,姜葆华,李永军.肾生髓理论的现代研究.中医杂志,1999,40(10);626～628.
76 李楠,戴锡孟.补肾方药对骨髓造血影响的实验研究进展.天津中医学院学报, 1994, (4); 44～46.
77 李佩文,赵建成.恶性肿瘤并发症实用疗法.中国中医药出版社.1995 年版.
78 冯璞,赵扬,罗崇念.补肾合剂对免疫缺陷小鼠造血功能的影响.中草药, 1998, 29 (11); 752～754.
79 邓成珊等.当代中西医结合血液病学.中医医药科技出版社,1997,362.
80 李美芬等.AM 促进小鼠粒系造血.湖南医科大学学报,1991,16(2);135-136.
81 李仪奎,姜名瑛等.中药药理学.北京中医药出版社,1992;183-187.
82 刘星皆,喻正坤.AM 成分和药理活性研究进展.上海医药,1995,16(20);23.
83 潘敏求,主编.中华肿瘤治疗大全.石家庄,河北科技出版社,1996,53.
84 刘辉,李金荣,胡传真.AM 对磷癌细胞株 GNM 荷瘤鼠的免疫增强及抑瘤作用的研究.口腔医学,1999,19(2);60-61.
85 王德昌等.黄芪多糖 FB 对人血淋巴细胞免疫功能的影响[J].中华肿瘤杂志, 1998, 11 (3);180.
86 黄兆生.中药学人民卫生出版社,2004,454.
87 李仪奎,姜名瑛等.中药药理学.北京中医药出版社,1992;183-187.
88 黄泌.免疫药物学[M].上海:上海科学技术出版社,1986,142-176.
89 黄兆生.中药学人民卫生出版社,2004,454.
90 李美芬等.黄芪促进小鼠粒系造血实验研究.湖南医科大学学报,1991,16(2);135-136.
91 王德昌等.黄芪多糖 FB 对人血淋巴细胞免疫功能的影响.中华肿瘤杂志,1998,11(3);180.
92 黄兆生.中药学人民卫生出版社,2004,454.
93 李仪奎,姜名瑛等.中药药理学.北京中医药出版社,1992,183-187.
94 黄兆生.中药学人民卫生出版社,2004,454.
1 裴雪涛.加强造血调控的基础与临床研究.中华血液学杂志.1998, 19(6); 283-284.
2 Broxmeyer HE, Kim CH. Regulation of hematopoiesis in a sea of chemokine family member with a Plethora of redundant activities EXP Hematol, 1999, 27; 113-1123.
3 Ziegler BL, Buhring HJ, Schedings, et al. cytokine reponses of hematopoietic Progenitor cells. in: Educational Program book. 98 ISH-EHA combined haemato Logu congress. Amsterdam, 1958, 51-57.
4 杨藻宸主编.医用药理学.第 3 版,北京:人民卫生出版社,1994,1023.
5 彭登慧,谢仁敷,田丰.补肾中药对注射环磷酰胺小鼠骨髓微循环障碍的影响.中西医结合杂志,1983,3(5);292.
6 TO LB, Haylock ON, Simmons PJ, ex ell. The biology and chinical uses of blood stem cells Blood, 1997, 89; 2233-2258.
7 TO LB, Haylock ON, Simmons PJ, ex ell. The biology and chinical uses of blood stem cells Blood, 1997, 89; 2233-2258.
8 李晓,浦汉,周艳贞等.细胞毒药物对急性白血病原位凋亡的诱导作用.上海第二医科大学学报,2001,21(1);57-59,87.
9 Williams GT, Smithc. Molecular regulation of apoptosis genetil controls on Celldeath.Cell, 1993:74.
10 魏晓超,蔺新力,王新娟.肿瘤坏死因子相关的凋亡诱导及其与肿瘤治疗前景,生理学进展,2001,32(1);8-22.
11 Bodine Dm, Crosier PS, Clark SC. Effects of hematopoietic growth fastors on the survival of primitive stem ells in Lignid suspension culture. Blood, 1991, 78; 914.
12 Macijewsk JP, Selleric, Sato T, et al. Nitrie oxide suppression of human hematopoiesis in vitro Contribution to inhibitory action of inter feron-gamma and tumor necrosis factor alpla. J clin invest, 1995, 96;1085.
13 Sugahara H. Ishikawa J. Hashimotok, et al. induction of programmed cell death in human hematopoitic cell lines by fibronectin via its interaction with wery late antigen 5. JEXP med, 1994, 179; 1757.
14 杨志祥,麋漫天.造血分化与细胞周期调控.国外医学输血及血液学分册,1999, 22 (2);
101-103.
15 霍中和,王喜忠,丁明孝主编.细胞生命学.北京:高等教育出版社,1995,8; 357-411.
16 Jacks T and Weinberg RA. The expanding role off cell cycle regulators Scienlce, 1998, 280; 1035.
17 董凌莉,刘文励.细胞粘附与细胞周期调控.中华血液学杂志,2000,7(21); 389-390.
18 曾益新主编.肿瘤学.北京:人民卫生出版社,1999,11;97-118.
19 吴祖泽,沈世人,朱爱武等.外周血造血干细胞性能和移植的实验研究.中国科学, 1980,(12);1228.
20 王声远,李真,马宜行.造血干细胞的研究Ⅱ.骨髓冻存后干细胞活力的测定.中华血液学杂志, 1981,2;133.
21 Civincl, Strausst LC, Brouall C, et al. Antigenic analysis of hematopoiesis, Ⅲ. A hemapoietic progeniceir cell surface antigen defined by a monoclonal antibody raised against KG-la cells. J lmmunol, 1984, 133; 157-165.
22 Bender JG, unverzagek, WalkweDE, et al. Phenotypic and characterization of CD34+ cells from normal human bone marron, cord blood, peripheral blood, and mobilized peripheral blood from Patients undergoing antologous stem cell transplantation. Clin Immunopath, 1994, 70; 10-18.
23 马思普,刘秀玲,韩颖等.低分子硫酸葡聚糖对 Beagle 狗外周血细胞动员作用的研究.中华血液学杂志,1996,17;251.
24 吴祖泽,贺福初,裴雪涛主编.造血调控.上海:上海医学大学出版社,2000,9;79-110.
25 陈彤,李佩,谢毅.造血干细胞表面的粘附分子及其在干细胞移植中的作用. 国外医学输血及血液学分册,2000,23(2);19-21.
26 To LB et al. The biology and chinieal uses of blood stem cells. Blood, 1997; 89:2233-2258.
27 Simmous PJ et al. Potential adhesion mechanisms for localization of heamopoieeic progenitors to bone marrow stroma. Lenkemi lymphoma, 1994, 12; 353-363.
28 Turner ML. Regulation of hematopoietic progenitor cell migration. Mobilization and homing stem cells, 1994, 12; 227-229.
29 Tavassolim & hard CL. Molelular basis of homing of intravenously transplant stem cells. Blood. 1990, 76;1059-1070.
30 黄文荣,张伯龙,达万明.粘附分子与造血干细胞移植.国外医学输血及血液学分册, 2000, 23(2);1-4.
31 Jacobson K et al. Adhesion receptors on bone marrow stroma cells in vivo expression of vascular cell adhesion molecule-l and by reticular cells and sinusoidal endothelium in normal and irradiated mice. Blood, 1996, 87; 73-82.
32 Papay dnnopoulot T & Nakamoto B. peripheralisation of hemopoietic progenitor in primates treated with auti-VLA-4 intergrin. Pro. Nat Acad scien USA, 1993, 90; 9374 -9378.
33 Janowska- wieczorek A et al. Growth factor and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. Blood, 1999, 93; 3379-3390.
34 Chabanon C et al. patient conclition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colong-stimulating factor. J Hem atother, 1995, 4; 171-175.
35 李战强,白庆咸,杨平地.趋化因子—基质细胞源性因子-1 与造血. 国外医学输血及血液学分册,1998,21(3); 156-158.
36 Mielcarek M, Reems J, Torok SB. Extrinsic control of stem cell fatepractical considerations. Stem cells, 1997; 15(suppl1): 229.
37 Joshi SS, Counolly J mann SL, et al. Altered in Vitro behavior of butanol-modified bone marrow. Cells, Exp Hematol, 1995; 23: 1284.
38 Hirsch E, lglesias A, Potocnik AJ, et al. Impaired migration but out differentiation of haematopoietic stem cells in the absence of βintegrins. Natnre, 1996, 380: [7] .
39 Turner ML, Sweeten ham JW. Haemopoietic Progenitor homing and mobilization. Br Haematol, 1996, 94: 592.
40 Wineman J, moorek, lemischka I, et al. Functinal heterogeneity of the hematopoietic microenviron ment; rare Stromal elements maintain long-term repopulating seem cells. Blood, 1996, 87; 4082-4090.
41达万明.MaDFF.骨髓移植后造血微环境重建的研究.中华血液学杂志,1987,(8);18-20.
42达万明,裴雪涛主编.外周血干细胞移植.北京:人民卫生出版社,2000,09;265-273.
43项莺松,梁志华.造血干细胞移植研究中的美学观.医学与哲学,1999,20(7):63-64.
44 林旭滨 , 刘天洁 , 陈运贤 . 造血基质细胞和造血干细胞移植 . 国外医学内科学分册,2001,28(3);112-115.
45刘天洁,林旭滨,陈运贤.基质细胞与造血干细胞移植后的造血重建.中国病理生理杂志,2000,16(5);474-477.
46Knospe WH, Husseini SG, Zipori, et al. Hematopoiesis on cellulose ester membranes. Ⅷ.A combinntion of cloned stromal cells is needed to establish a hematopoietic microenvironment supportive of trilineal hematopoiesis [J]. EXP Hematol, 1993,21;257.
47孙岚,刘文励.VEGF 及其受体调节造血细胞生长的作用.临床血液学杂志.2000, 13(6); 284-285.
48吴岩,祝彼得.内皮细胞与造血调控的研究.国外医学输血及血液学分册,2001,24(1); 9-13.
49滕小伟,赵佼,谭文松.内皮细胞在调控造血中的作用.国外医学输血及血液学分册,2001,24(1); 16-18.
50Klein G. The extracell ular matrix of the hematopoietic miroenviroment[J]. Experientia, 1995, 51;914.
51成军.细胞外基质的分子生物学与临床疾病.北京:北京医科大学出版社,1999,6;196-204.
52Suito M. Recent trends in research on differentiation of hematopoietic cells and lymphokines(hemopoietins). Hum cell ,1992,5;54.
53达万明,裴雪涛主编.外周血干细胞移植.北京:人民卫生出版社,2000,9;5-6.
54Rose-John S, Heinrich PC. Soluble releptors for cytokines and growth factors: generation and biological function. Biochem J, 1994, 300; 281.
55Herington AC, Ymer S, Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J clin lnvest, 1996; 77:1817.
56Spriggs MK, Hruby DE, maliszewski CR, et al. vaccinia and viruses encode anovel secreted interleukin-l-binding protein. cell, 1992, 71;145.
57Yamazaki K, Yamada E, Kanaji Y, et al. interleukin-6 (IL-6) inhibite theroid function inthe present of soluble IL-6 receptor in cnlture human thyoid follicles. Endocrinology, 1996, 137; 4857.
58吴祖泽,贺福初,裴雪涛主编.造血调控.上海:上海医科大学出版社, 2000,9;128-153.
59Bergelson S, Socolovsky M, Hsiao JG, et al. Tyrosine residues within the intercellular domain of the erythropoietin receptor mediate activation of AP-1 trans cription factors. J Boil chem, 1998,273;2396.
60Hunter T. protein kinases and phosphateses: the Yin and Yang of protein phosporylatio and signaling. Cell, 1995, 80;225.
61Pelech SL, Sanghera JS. mitogen-activated protein kinases versatile transducers for cell signaling. TLBS, 1992,17;233.
62Bumer KJ, Johnson GL. diversity in function and regulation of MAP kinase pathway. trenls.Biochem Sic, 1995,19; 236.
63刘永学,贺福初,吴祖泽.生长因子及细胞因子的两条重要信息传导通路.生物化学与生物物理进展,1996,23;4.
64Levg DE. The house that JAK/STAT built. Cytokine Growth factor Rev, 1997, 8;81.
65Sakatsllme M, Stancato LF, David M, et al. interferon gamma sctivation of Raf-l is Jak1-dependent and p21ras independent.J Bool Chem, 1998, 273; 3021.
66Malarkey K, Belham CM, Paul A, et al. the regulation of tyrosine signaing pathways by factor and G-protein-Couplesd receptors. Biochem J, 1995, 309; 361.
67Bredt S, Snyder SH. Nitric oxide: A Physiolongic messenger molecule. Annu Rew Biochem, 1994, 63; 175-195.
68Fukuto JM, Chandhuri G. inhibition of constitutive and inducible NOS: Potential selective inhibition. Annu Rew Pharmacol Toxicol, 1995; 35:165-194.
69Cross SS. Wolin MS. Nitric oxide: pathophysiologica mechanisms. Annu Rew phsiol, 1995, 57; 737-769.
70肖学艺,吕国蔚.一氧化氮的生物学特征和作用.首都医科大学学报,1999,20(4);311-314.
71李中东,晏家益,吴群林.一氧化氮对血液系统的调节作用.国外医学输血及血液学分册,1999,22(4);254-256.
72Kamijo R, Harada H, Matsuyama T, et al. Reguirement for transcription factor IRF-lin NO synthase induction macrophages. Science , 1994, 263; 1612-1615.
73Macijewsk JP, selleric, saato, et al. Nitric oxide suppression of human hematopoiesisin Vitro contribution to inhibitory action of interferon-gamma and tumor necrosis factor alpha. J clin invest, 1995, 96; 1085.
74 Rafferty SP. Domachowske JB, malech HL.Inhibitorm of hemoglobin expression by hetorolognos peoduction of nice oxide synthase in the K562 erythroleukemic cell line. Blood, 1996, 88; 1070-1078.
75Forrester K, Ambs S. Lupold SE. et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric synthase expression by Wild-type p53. Proc Natl Acad sci USA, 1996, 93; 2442-2447.
76罗高光,徐秋萍.一氧化氮对细胞凋亡的影响[J].国外医学,临床生物化学与检验学分册,1997,18(40);145-146.
77于文强,孙秉中.一氧化氮与造血调控.中华血液学杂志,1998,19(10);557-559.
78张彩,田志刚.肿瘤免疫逃逸机制的研究进展.国外医学肿瘤学分册,2000,27(2);77-78.
79汤钊猷主编.现代肿瘤学.第二版,上海:上海医科大学出版社,2000;9:239-293
80王振义,陈竺主编.肿瘤的诱导分化和调亡疗法.上海:上海科技出版社,1998;1-10.
81张劲旅,张锦堃.人血树突状细胞研究进展.国外医学输血及血液学分册, 1998, 21 (5); 302-305.
82孙恺,张茂宏,田志刚等.LAK 细胞和活化 NK 细胞对小鼠骨髓造血功能影响的实验研究.中华血液学杂志,1999,20(8);405-408.
83 郭 宝 刚 , 田 志 刚 .NK 细 胞 亚 群 及 其 对 造 血 的 调 节 效 应 . 国 外 医 学 肿 瘤 学 分册,1997,24(3);139-140.
1 李佩文.中西医结合临床肿瘤学.中国中医药出版社,1996,244.
2 田卫卫,王庆苗.恶性肿瘤化疗后骨髓抑制的病机及临床治疗探讨.河北中医, 2000,22(10);791～792.
3 扬晓峰,王锐,邱根全.孙喜才治疗肿瘤放化疗后白细胞减少症经验拾零.山西中医, 2000, 10(16);7～8.
4 田振典,李苏宣,阚全程等.归脾汤加减干扰化疗后白细胞下降序贯试验.河南医科大学学报,1996,31(2);80～81.
5 刘嵚,姚力峰.辨证论治化疗后白细胞减少症 32 例疗效观察.中国中医药信息杂志,1998,5(7);33～34.
6 吴荻,张越,刘敬伟.补气养血法治疗非霍奇金淋巴瘤化疗致白细胞减少 46 例.吉林中医药,2002,22(1);17.
7 蔡宇,赵益亚,金君梅.化疗所致骨髓抑制的中医药辨证.吉林中医药,1998,(1);1.
8 田振典,李苏宣,阚全程等.归脾汤加减干扰化疗后白细胞下降序贯试验.河南医科大学学报,1996,31(2);80～81.
9 吴荻,张越,刘敬伟.补气养血法治疗非霍奇金淋巴瘤化疗致白细胞减少 46 例.吉林中医药,2002,22(1);17.
10 刘振学.当归补血汤对减轻放化疗骨髓抑制的初步观察.实用中西医结合杂志, 1993, (3); 166.
11 张子丽,刘影,刘子厚.八珍汤加味治疗放疗及化疗所致的白细胞减少症.实用肿瘤学杂,1996,10(3);43～44.
12 李月华,朱海婴,叶启霞等.气血葆口服液对放化疗毒性作用的影响.中国中医药信息杂志,1996,3(7);13.
13 李明众,赵东利,王书文.复方皂矾丸对恶性肿瘤病人放化疗骨髓保护及升白作用.西北药学杂志,1998,13(2);80～81.
14 宋海洪,陈泽涛,齐元意等.参莲温胆合剂治疗化疗所致的白细胞和血小板减少的临床观察和实验研究.上海中医杂志,1997,10(2);13.
15 赵国华,张新,戴卫东.半夏泻心汤在食管癌化疗中减毒作用的临床观察.中医研究,1996,9(2);40～41.
16 苗文红.补肾健脾法治疗肿瘤放化疗所致的骨髓抑制 98 例.陕西中医,2000,21(7);289.
17 王玉华,曲士杰,郭郁.扶正培本法防治肿瘤化疗后白细胞血小板减少.中国民间疗法,2001,21(7);289.
18 李永安,李国庆.化疗中气阴两虚证的辨证治疗.四川中医,2002,20(1);14.
19 林能明,陈晓钟,郑晓等.生白宝口服液治疗恶性肿瘤放化疗引起的白细胞减少症的临床观察.肿瘤防治研究, 1995,22(6);392.
20 齐元富,钱伯文.肿瘤血瘀证及活血化瘀治疗的现代研究进展.中医杂志,1993,34 (6); 370～373.
21 刘承煌.胸部恶性肿瘤患者的甲皱微循环表现.中华肿瘤杂志,1986,8(4);250 .
22 施永德.恶性肿瘤病人的紫舌和血液流变学分析.中华肿瘤杂志,1981,3(3);222 .
23 王笑天.癌证患者的瘀血证与血液高凝状态的研究.中国中西医结合学会活血化瘀研究学会编.血液证与活血化瘀研究.北京:学苑出版社,1990,260.
24 齐元富,钱伯文.肿瘤血瘀证及活血化瘀治疗的现代研究进展.中医杂志,1993,34 (6); 370～373.
25 纪树国.肺癌患者凝血状态的现象.肿瘤防治研究,1990,17(2);82.
26 陈泽霖.恶性肿瘤青紫舌病人的血液流变学和微循环观察.吉林中医药,1984,(3);27.
27 李佩文.中西医结合临床肿瘤学.中国中医药出版社,1996,244.
28 马振亚.中药方剂免疫机理研究.西安:陕西科技出版社,1986,14.
29 蔡宇,赵益亚,金君梅.化疗所致骨髓抑制的中医药辨证.吉林中医药,1998,(1);1.
30 李佩文.中西医结合临床肿瘤学.中国中医药出版社,1996;244.
31 王玉华,曲士杰,郭郁.扶正培本法防治肿瘤化疗后白细胞血小板减少.中国民间疗法, 2001,21(7);289.
32 赵省,赵宏亮,宋长河.丹参防治肿瘤化疗所致骨髓抑制的研究.河南肿瘤学杂志,1994, 7(2);134～135.
33 刘俊杰,周成运.苦参素注射液治疗 56 例肿瘤化疗后白细胞减少症.肿瘤学杂志, 2005, 11(2):155-156.
34 李佩文.中医药治疗化疗毒副反应的现状与展望.中国中医药信息杂志,1996,3(1);22.
35 田振典,李苏宣,阚全程等.归脾汤加减干扰化疗后白细胞下降序贯试验.河南医科大学学报,1996,31(2);80～81
36 刘振学.当归补血汤对减轻放化疗骨髓抑制的初步观察.实用中西医结合杂志,1993, (3); 166
37 张子丽,刘影,刘子厚.八珍汤加味治疗放疗及化疗所致的白细胞减少症.实用肿瘤学杂, 1996,10(3);43～44.
38 竹川佳宏.汉方と最新治疗.2001,10(2);185～188.
39 苗文红.补肾健脾法治疗肿瘤放化疗所致的骨髓抑制 98 例.陕西中医,2000,21(7);289.
40 刘少翔,陈志峰,胡海山.中医药与磁疗防治放化疗后副作用的临床研究.辽宁中医杂志, 1995,22(2);64.
41 王迎红,王怀璋,余永虎.中药对癌证化疗后骨髓保护作用的临床研究.河南中医药学刊, 2000,15(6);64～65.
42 王玉华,曲士杰,郭郁.扶正培本法防治肿瘤化疗后白细胞血小板减少.中国民间疗法, 2001,21(7);289.
43 李明众,赵东利,王书文.复方皂矾丸对恶性肿瘤病人放化疗骨髓保护及升白作用.西北药学杂志,1998,13(2);80～81.
44 张蕾.升白汤合复方皂矾丸治疗化疗后白细胞减少80例.现代中西医结合杂志,2002, 11 (11);1023.
45 文灿途,缪英年,陈茂潮.健脾益肾饮治疗化疗后白细胞减少症.湖北中医杂志,2002,24 (1);28.
46 张宏,李国康.增髓汤对乳腺癌术后化疗改善骨髓抑制的研究.实用中医杂志,2005,21 (13):1481-1482.
47 陈闯.化疗后白细胞减少症的疗效分析.甘肃中医,1999,12(3);22～23.
48 孙隆生,朱新勇,于秋华.癌血生合剂纠正肿瘤放化疗骨髓抑制 100 例分析.肿瘤防治研究, 1994,21(3);190～191.
49 杨泽江,李志革,黄秉琰.生血宝防治化疗所致骨髓抑制 13 例临床观察.湖南中医杂志, 1997,13(3);20～22.
50 林能明,陈晓钟,郑晓等.生白宝口服液治疗恶性肿瘤放化疗引起的白细胞减少症的临床观察.肿瘤防治研究,1995,22(6);392.
51 李月华,朱海婴,叶启霞等.气血葆口服液对放化疗毒性作用的影响.中国中医药信息杂志,1996,3(7);13.
52 宋海洪,陈泽涛,齐元意等.参莲温胆合剂治疗化疗所致的白细胞和血小板减少的临床观察和实验研究.上海中医杂志,1997,10(2);13.
53 赵国华,张新,戴卫东.半夏泻心汤在食管癌化疗中减毒作用的临床观察.中医研究, 1996, 9(2);40～41.
54 刘嵚,姚力峰.辨证论治化疗后白细胞减少症32例疗效观察.中国中医药信息杂志,1998, 5(7);33～34.
55 吴荻,张越,刘敬伟.补气养血法治疗非霍奇金淋巴瘤化疗致白细胞减少 46 例.吉林中医药,2002,22(1);17.
56 李永安,李国庆.化疗中气阴两虚证的辨证治疗.四川中医,2002,20(1);14.
57 吴德峰.六神散治疗化疗后白细胞减少症 50 例.江苏中医药,2002,23(10);27.
58 朱俐俐,郭立新.益气养阴法治疗化疗后白细胞减少32例.江苏中医药,2002,23(1);22-23.
59 李松林.参麦针合中汤药防治肿瘤化疗后白细胞减少症 39 例.陕西中药,2003,24 (12); 1064-1065.
60 何文华,杨维春,张宏江,等.地榆升白片加粒细胞集落刺激因子预防化疗后骨髓抑制临床观察.中国中医药信息杂志,2005,12(11);77.
61 胡欣,李戈,王子鑫等.穴注配合参附注射液治疗肿瘤化疗后白细胞减少症 30 例.实用中医内科杂志,2006,20(3);341-342.
62 唐新星.中药穴位注射配合内服治疗化疗后白细胞减少症 24 例.安徽中医临床杂志, 2001,13(1);39-40.
63 邢海平,王天昌,王俊生.博生癌宁透皮药贴对恶性肿瘤化疗后骨髓抑制的保护作用.中医研究,1998,11(3);24～25.
64 冯璞,赵扬,罗崇念.补肾合剂对免疫缺陷小鼠造血功能的影响.中草药,1998,29(11); 752～754.
65 李振波,丘和明,刘国普.清毒饮和养正片对环磷酰安所致的造血抑制小鼠粒系造血的影响.广州中医药大学学报,1999,16(1);34～37.
66 廖军祥,谢仁敷,郭惟.补肾活血方对骨髓造血作用的病理及电镜观察.实用中西医结合杂志,1991,4(12);731～732.
67 吴志奎,姜葆华,李永军.肾生髓理论的现代研究.中医杂志,1999,40(10);626～628.
68 竹川佳宏.汉方と最新治疗,2001,10(2);185～188.
69 北原正和.汉方と最新治疗, 2001,10(2);189～192.